By: IPP Bureau
Last updated : February 21, 2025 10:35 am
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Wanbury Ltd., a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter and nine months ended December 31st, 2024.
The company has posted 88.1 per cent drop in its Q3 FY25 PAT at Rs. 1.2 crore as compared to Rs. 10.3 crore in Q3 FY24. Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25 as compared to Rs. 145.5 crore in Q3 FY24.
Revenue from operations & EBITDA for Q3FY25 stood at Rs. 133.5 crores and Rs. 14.8 crores respectively compared to revenue from operations Rs. 145.5 crores & EBITDA Rs. 21.8 crores respectively in previous year quarter. This decline was due to shutdown of the Tanuku manufacturing facility for scheduled major upgradation and capacity expansion for 30 days thereby temporarily impacting revenue & EBITDA for the quarter.
Mohan Rayana, Director ofWanbury Ltd., said, "We are pleased to report the Q3FY25 results, demonstrating resilience despite the shutdown of our Tanuku facility for scheduled major upgradation and capacity expansion, for 30 days, temporarily impacting revenue and profitability during the quarter. We continue to strengthen our API portfolio by expanding customer base and broadening our geographic presence with plans to accelerate growth through near term launch of three new APIs.”